Tyrosine Kinase Inhibitor
Tuspetinib for Acute Myeloid Leukemia
This trial is testing a new drug, HM43239, for patients with relapsed or refractory acute myeloid leukemia (AML). The goal is to find the safe dose range and to see how well the drug works.
Anti-tumor antibiotic
BH-30236 for Acute Myeloid Leukemia and Myelodysplastic Syndrome
"This trial is studying a new drug for people with relapsed or refractory acute myelogenous leukemia or higher-risk myelodysplastic syndrome. The study has two phases: Phase 1
Popular Filters
Trials for Megakaryoblastic Leukemia Patients
CAR T-cell Therapy
JNJ-75276617 Combination Therapy for Acute Myeloid Leukemia
This trial tests JNJ-75276617, an oral drug that blocks a key protein interaction in leukemia cells. It targets adults with AML who have specific genetic changes making their disease hard to treat. The drug aims to stop cancer cells from growing and spreading.
Chemotherapy
DSP-5336 for Leukemia
This trial is testing a new drug called DSP 5336 to help treat adults with certain types of blood cancer that have come back or didn't respond to previous treatments. The study will first find the best amount to give and then check how safe and helpful it is.
Chemotherapy
CC-91633 for Leukemia
This trial tests a new drug, CC-91633, for patients with certain blood cancers that haven't responded to other treatments. Researchers will find the safest dose by increasing it over time and checking for side effects and effectiveness.
Behavioural Intervention
High-Fiber/Low-Fat Diet for C. diff Infection Prevention in Cancer Patients
This trial is testing if a diet with more fiber and less fat can help prevent C. difficile infections from coming back in cancer patients. The idea is that this diet might improve gut health by supporting good bacteria and reducing bad bacteria.
Trials for Acute Promyelocytic Leukemia Patients
CAR T-cell Therapy
JNJ-75276617 Combination Therapy for Acute Myeloid Leukemia
This trial tests JNJ-75276617, an oral drug that blocks a key protein interaction in leukemia cells. It targets adults with AML who have specific genetic changes making their disease hard to treat. The drug aims to stop cancer cells from growing and spreading.
Chemotherapy
DSP-5336 for Leukemia
This trial is testing a new drug called DSP 5336 to help treat adults with certain types of blood cancer that have come back or didn't respond to previous treatments. The study will first find the best amount to give and then check how safe and helpful it is.
Chemotherapy
CC-91633 for Leukemia
This trial tests a new drug, CC-91633, for patients with certain blood cancers that haven't responded to other treatments. Researchers will find the safest dose by increasing it over time and checking for side effects and effectiveness.
Behavioural Intervention
High-Fiber/Low-Fat Diet for C. diff Infection Prevention in Cancer Patients
This trial is testing if a diet with more fiber and less fat can help prevent C. difficile infections from coming back in cancer patients. The idea is that this diet might improve gut health by supporting good bacteria and reducing bad bacteria.
Trials for FLT3 Positive Patients
Chemotherapy
DSP-5336 for Leukemia
This trial is testing a new drug called DSP 5336 to help treat adults with certain types of blood cancer that have come back or didn't respond to previous treatments. The study will first find the best amount to give and then check how safe and helpful it is.
Chemotherapy
Ziftomenib Combinations for Acute Myeloid Leukemia
This trial will test the safety and effectiveness of a drug called ziftomenib when used together with standard treatments for patients with a type of blood cancer called acute myeloid leukemia that has come back
CAR T-cell Therapy
Genetically Modified T-cell Therapy for Leukemia
This trial is testing the side effects and best dosage of genetically modified T-cells, which are a type of immune cell, in patients with leukemia or a certain type of cancer of the blood and bone marrow.
Tyrosine Kinase Inhibitor
Gilteritinib + Azacitidine for Acute Myeloid Leukemia
This trial is testing an experimental drug, ASP2215 (gilteritinib), on patients recently diagnosed with AML. AML is cancer of the bone marrow where abnormal white blood cells are produced. The trial will compare the effects of ASP2215 with the standard of care treatment, azacitidine (Vidaza®), on patients' overall survival.
Anti-metabolites
Azacitidine + Nivolumab/Midostaurin vs. Decitabine/Cytarabine for Acute Myeloid Leukemia
This trial is studying azacitidine with or without nivolumab or midostaurin, or decitabine and cytarabine alone to see how well they work compared to each other in treating patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
Trials for IDH Positive Patients
Chemotherapy
DSP-5336 for Leukemia
This trial is testing a new drug called DSP 5336 to help treat adults with certain types of blood cancer that have come back or didn't respond to previous treatments. The study will first find the best amount to give and then check how safe and helpful it is.
IDH1 Inhibitor
Ivosidenib + Azacitidine for Acute Myeloid Leukemia
This trial is testing a new oral drug, ivosidenib, combined with an injectable drug, azacitidine. It targets adults with a specific type of untreated leukemia who can't undergo intensive treatments. Ivosidenib blocks a faulty enzyme in cancer cells, and azacitidine stops these cells from growing.
IDH1 Inhibitor
AG-120 for Blood Cancers
This trial is testing a new drug, AG-120, to see if it's safe and effective in treating people with advanced cancers that have a mutation in the IDH1 gene. The trial has two parts: first, they'll test different doses of the drug to see what the maximum tolerated dose is; then, they'll expand the trial to a larger group of people to see if the drug is effective. There's also a substudy testing AG-120 in people with a different but related cancer, myelodysplastic syndrome.
IDH Inhibitor
AG-120 or AG-221 Combination Therapy for Acute Myeloid Leukemia
This trial is studying AG-120 and AG-221 to see if they are safe when given with standard AML induction and consolidation therapy and to find the maximum tolerated dose of each drug.
IDH2 Inhibitor
Enasidenib + Azacitidine for Acute Myeloid Leukemia
This trial studies enasidenib and azacitidine in patients with acute myeloid leukemia (AML) that has come back or does not respond to treatment. These patients have a specific gene mutation called IDH2. The drugs work by blocking enzymes that cancer cells need to grow. Enasidenib is approved by the US FDA for adults with relapsed or refractory AML with an IDH2 mutation.
Phase 3 Trials
IDH1 Inhibitor
Ivosidenib + Azacitidine for Acute Myeloid Leukemia
This trial is testing a new oral drug, ivosidenib, combined with an injectable drug, azacitidine. It targets adults with a specific type of untreated leukemia who can't undergo intensive treatments. Ivosidenib blocks a faulty enzyme in cancer cells, and azacitidine stops these cells from growing.
Radioimmunotherapy
Iomab-B + HCT for Acute Myeloid Leukemia
This trial is testing a new treatment for AML patients who have relapsed or are unresponsive to other treatments. The new treatment consists of a reduced intensity conditioning regimen in conjunction with Iomab-B and allogeneic hematopoietic stem cell transplant.
BCL-2 Inhibitor
Venetoclax + Azacitidine for Acute Myeloid Leukemia
This trial is testing a new combination treatment for acute myeloid leukemia (AML), a cancer of the blood and bone marrow. The treatment consists of the experimental drug venetoclax, which kills cancer cells by blocking a protein that allows them to stay alive, combined with azacitidine. The study will enroll approximately 400 participants globally and will compare the efficacy of the new combination treatment to azacitidine alone.
Trials With No Placebo
CAR T-cell Therapy
JNJ-75276617 Combination Therapy for Acute Myeloid Leukemia
This trial tests JNJ-75276617, an oral drug that blocks a key protein interaction in leukemia cells. It targets adults with AML who have specific genetic changes making their disease hard to treat. The drug aims to stop cancer cells from growing and spreading.
Chemotherapy
DSP-5336 for Leukemia
This trial is testing a new drug called DSP 5336 to help treat adults with certain types of blood cancer that have come back or didn't respond to previous treatments. The study will first find the best amount to give and then check how safe and helpful it is.
Chemotherapy
CC-91633 for Leukemia
This trial tests a new drug, CC-91633, for patients with certain blood cancers that haven't responded to other treatments. Researchers will find the safest dose by increasing it over time and checking for side effects and effectiveness.
Behavioural Intervention
High-Fiber/Low-Fat Diet for C. diff Infection Prevention in Cancer Patients
This trial is testing if a diet with more fiber and less fat can help prevent C. difficile infections from coming back in cancer patients. The idea is that this diet might improve gut health by supporting good bacteria and reducing bad bacteria.
View More Related Trials
Frequently Asked Questions
Introduction to aml
What are the top hospitals conducting aml research?
Houston's MD Anderson Cancer Center takes the lead in clinical trials for acute myeloid leukemia (AML), with an impressive 13 active trials and a total of 92 trials conducted thus far. This renowned institution has been at the forefront of AML research since recording its first trial in 2001, showcasing unwavering dedication to finding new treatments and improving patient outcomes. Meanwhile, Massachusetts General Hospital in Boston is also making substantial contributions to AML research, actively conducting 10 trials and having completed 70 studies since their initial trial in 2003.
Notably, another Texas-based hospital—MD Anderson Cancer Center—shares the same name but operates independently from its Houston counterpart. This M D Anderson facility boasts an equally impressive track record with AML research: they currently have ten ongoing clinical trials and have participated in a remarkable total of 93 studies since initiating their inaugural trial back in1999.
Further adding to this list is City of Hope located in Duarte, California. Although it may have fewer active AML trials compared to some others on this list—with nine currently underway—it still holds significant importance within the field as it has contributed to advancing knowledge through a notable number of previous thirty-eight investigations that began all the way backin2004.
Lastly, Roswell Park Cancer Institute situated in Buffalo deserves recognition for its extensive efforts devoted to combating AML. With nine ongoing clinical trials tackling this challenging disease and an astonishing tally of107 previously completed studies dating backto1997,it remains a pivotal institution dedicated to unraveling mysteries surrounding effective treatment options for patients battling AML.
These hospitals exemplify dedication towards understanding and treating acute myeloid leukemia while driving forward medical innovation. Their collective efforts bring hope not only those directly impacted by this aggressive blood cancer but also encourage progress that ultimately benefits individuals worldwide facing similar challenges.
Which are the best cities for aml clinical trials?
When it comes to AML clinical trials, several cities stand out as top destinations for research. Boston, Massachusetts leads the way with 49 active trials investigating treatments like AG-120, CC-90009, and cytarabine. New york City closely follows with 47 ongoing studies focusing on CC-486, Cytarabine, and Oral Azacitidine. Houston, Texas and Chicago, Illinois tie with 46 active trials each exploring treatments such as Venetoclax and AG-120. Lastly, Saint Louis in Missouri offers 24 active trials studying medications like CC-90009 and Cytarabine. These cities provide individuals with access to cutting-edge AML clinical trials that hold promise for improved treatment options and better outcomes.
Which are the top treatments for aml being explored in clinical trials?
Clinical trials are paving the way for potential breakthroughs in treating acute myeloid leukemia (AML). Among the top contenders, venetoclax emerges as a frontrunner with eight active trials and an impressive track record of 130 all-time AML trials since its debut in 2014. Cytarabine follows closely, participating in five ongoing studies and boasting a remarkable 246 all-time AML trials since its introduction in 2001. Another promising treatment is liposome-encapsulated Daunorubicin-Cytarabine, currently involved in five active trials and showing promise since it was listed in 2015. Pevonedistat, with three active trials, and CPX-351, with two active trials round out this select group of groundbreaking therapies being explored to combat AML. These ongoing efforts bring hope to those affected by this challenging disease.
What are the most recent clinical trials for aml?
Exciting advancements are being made in the field of acute myeloid leukemia (AML) with recent clinical trials offering new possibilities for treatment. One notable trial is investigating the effectiveness of Meropenem as a potential therapy for AML patients, providing insights into its efficacy and safety. Additionally, another trial focuses on determining the optimal dosage level in Phase 1 patients receiving novel treatments for AML. Moreover, Regimen A: TBI/Thiotepa/Cyclophosphamide explores a combination approach to combat this aggressive form of leukemia. These ongoing studies offer hope and promise to those affected by AML, pushing forward our understanding and options for managing this challenging disease.
What aml clinical trials were recently completed?
Recently completed clinical trials in the field of acute myeloid leukemia (AML) include various innovative investigations. In June 2021, AbbVie concluded a trial examining Lemzoparlimab as a potential treatment option. Additionally, Pfizer's Azacitidine trial reached completion in May 2021. Last year, Bhavana Bhatnagar successfully wrapped up a Dubermatinib study in November 2020, while Rutgers, The State University of New jersey finalized their Salsalate trial in October of the same year. These recent advancements highlight ongoing efforts to advance AML treatments and offer hope for patients grappling with this challenging disease.